GSK plc (FRA:GS71)

Market Cap	86.94B +33.0%
Revenue (ttm)	36.85B +2.7%
Net Income	6.29B +118.8%
EPS	1.52 +118.6%
Shares Out	n/a
PE Ratio	13.81
Forward PE	10.34
Dividend	0.75 (3.47%)
Ex-Dividend Date	Nov 13, 2025

Volume	550
Average Volume	1,103
Open	21.08
Previous Close	21.08
Day's Range	21.08 - 21.59
52-Week Range	14.68 - 21.94
Beta	n/a
RSI	59.86
Earnings Date	Feb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a...

• Industry: Pharmaceutical Preparations
• Founded: 1715
• Employees: 68,629
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GS71

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP